Muttenz

Researchers are creating a European registry and sample sharing network called EUREKA to collect all new cases of systemic AL amyloidosis from referral centers across Europe. This project aims to use advanced molecular technologies and big data analysis, including artificial intelligence, to better understand the disease mechanisms. The study focuses on improving early diagnosis, guiding treatment decisions, describing the disease course in patients, and detecting minimal residual disease after therapy. The registry will gather patient data along with biological samples for detailed molecular analysis of disease-causing light chains and plasma cells. A dedicated site will support the consortium with data analysis using advanced computational methods. This approach intends to refine technologies that detect residual disease with high sensitivity in patients who have achieved complete hematologic response to treatment. Participants will be followed over time at participating centers, with data collected on their clinical outcomes. The main outcome measure is mortality at 24 months from diagnosis. Patients will provide informed consent, and their disease progression and treatment responses will be monitored to understand the natural history of AL amyloidosis in the current era of effective therapies.